Subscribe

In Search of £1 Million to Confirm Value of First Genetically Engineered Oncolytic Virus for Neuroendocrine Cancer

VBCC - June 2013, Volume 4, No 5 - Value Propositions

Neuroendocrine cancer, a rare type of cancer (that became well known after Steve Jobs was diagnosed with and died from a neuroendocrine cancer of the pancreas), may have a new lease on life, if Swedish researchers of Uppsala University in Sweden find a way of obtaining £1 million (approximately $1.5 million) to support their research. “We have developed a virus that was effective in mice, but it’s been in the freezer for the past two years because the trials in humans are too expensive for an academic center,” said Magnus Essand, MD, PhD, Professor of Neuroendocrine Cancer, Uppsala University, Sweden. Because of early publication of the results, the researchers will not be able to have a patent protection for the virus, thereby thwarting any chance of commercializing and profiting from their research. Instead, they have launched a fundraising campaign online at www.uu.se/en/support/oncolytic/.

According to the website, “The treatment consists of an oncolytic virus, which has turned out to be remarkably efficient in destroying neuroendocrine tumours in mice.” Why donate? “If you donate the equivalent of one million pounds, we will name the world’s first genetically engineered neuroendocrine-specific virus in your honour….Like other virus treatments for cancer that are in development around the world, this virus is predicted to be safe and have few side-effects in humans.”

If they get the funding, Professor Kjell Öberg, current Chairman of the European Neuroendocrine Tumor Society, will launch the world’s first human trials with this genetically engineered virus designed to target neuroendocrine tumors. (Uppsala University, Sweden; May 2013)
 

Related Items
Value Propositions - April 2018
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Value Propositions
Value Propositions - October 2017
VBCR - October 2017, Vol 6, No 4 published on October 20, 2017 in Value Propositions
Value Propositions - August 2017
VBCR - August 2017, Vol 6, No 3 published on August 23, 2017 in Value Propositions
Value Propositions - June 2017
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in Value Propositions
Value Propositions - April 2017
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in Value Propositions
Value Propositions - December 2016
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Value Propositions
Value Propositions - October 2016
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Value Propositions
Value Propositions - August 2016
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Value Propositions
Value Propositions - June 2016
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Value Propositions
Value Propositions - April 2016
VBCR - April 2016, Vol 5, No 2 published on May 14, 2016 in Value Propositions
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology